Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-22-049923
Filing Date
2022-09-14
Accepted
2022-09-14 16:24:24
Documents
2
Period of Report
2022-09-12

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1621
2 POA DOCUMENT poa.txt EX-24 3771
  Complete submission text file 0001209191-22-049923.txt   6864
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Issuer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NURIX THERAPEUTICS 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address
Saltzman Edward C (Reporting) CIK: 0001946233 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39398 | Film No.: 221243245